Study of the link between Dopamine Transporter Gene Polymorphisms and Response To Paroxetin and Escitalopram in Patients With Lifelong Premature Ejaculation - Dopamine transporter gene polymorphisms and SSRIs
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 80
研究概览
简要总结
Our prospective study revealed that 18 patients were LL, 42 patients were SL and SS genotypes of the serotonin transporter gene promoter polymorphism, meanwhile; the controls were 10 LL, 6 SL and 4 SS which was statistically insignificant (p-value=0.265). Thirty seven patients were 10R/10R, 17 patients were 6R/10R and 6 patients were 6R/6R genotypes of the dopamine transporter gene polymorphism, meanwhile; the controls were 15 6R/6R, 1 10R/10R and 4 6R/10R which was statistically significant (p-value=<0.001). Both paroxetin and escitalopram were highly statistically significant in delaying ejaculation in the responders (p-value=<0.001). This response was irrelevant to serotonin transporter gene promoter polymorphism (p-value= 0.275), meanwhile; such response revealed highly statistically significant relation with dopamine transporter gene polymorphism (p-value=0.019).
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 25years-old 至 50years-old（—）
- 性别
- Male
入选标准
- 未提供
排除标准
- •Men suffered from ED (IIEF score< 21), reduced sexual desire or inhibited male orgasm. Also, patients with history of urinary tract infection, mental disorders and chronic physical illnesses affecting ejaculatory function, abusers of Alcohol or drug and finally, patients who received psychotropic medications that may affect response to selective serotonin reuptake inhibitors (SSRIs) or any medical treatment for premature ejaculation in the last 6 months were also excluded from the study.